GlassScriptPhysician profile
Tanya Paschen
NPI 1184171597
$3,019.97
in general payments reported to CMS, 2019-2025
42 companies · $507 in 2025
The $507 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $584 · 2022: $523 · 2023: $605 · 2024: $801 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $641.83 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $299.56 | 2021-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $232.92 | 2021-2025 | Caplyta |
| Glaxosmithkline, LLC. | $186.83 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $149.30 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $148.96 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $120.34 | 2021-2023 | Xarelto |
| Sumitomo Pharma America, INC. | $106.31 | 2023-2024 | Gemtesa, Aptiom |
| Sunovion Pharmaceuticals INC. | $105.67 | 2021-2022 | |
| Novo Nordisk INC | $105.14 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $86.42 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $85.26 | 2022-2025 | Airsupra |
| Corium, LLC | $69.08 | 2023 | Adlarity |
| Mylan Specialty L.P. | $66.34 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $54.19 | 2023-2024 | Uzedy, Austedo Xr |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Paschen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.